WA-TWIN-PROTOCOL
20.6.2024 09:31:27 CEST | Business Wire | Press release
Twin Protocol, a pioneer in the development of ethically engineered, personalized generative artificial intelligence (AI) technology to foster a culture of continuous knowledge sharing, announces a partnership with wellness and tech leaders, Cyberhuman.ai, and Dectec. The three companies are developing cutting-edge solutions that will democratize well-being and guide people around the world on the path of improved health and mindfulness. At the Cannes Creative Festival this week, Dr. Deepak Chopra unveils the first step in this revolutionary approach to sharing well-being knowledge across the globe – his Digital Deepak AI Twin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620183427/en/
Celebrating innovation at Cannes Creative Festival 2024: (pictured from left to right) Bill Inman, CEO of Dectec; Stacey Engle, CEO of Twin Protocol; Deepak Chopra, MD; and Poonacha Machaiah, Co-founder of Cyberhuman.ai., announce the groundbreaking Deepak Chopra AI Twin, a collaboration at the intersection of well-being, AI, and technology. (Photo: Business Wire)
World-renowned pioneer in integrative medicine and personal transformation, Dr. Deepak Chopra previews his digital twin to further his efforts to make chronic disease optional. Digital Deepak is a groundbreaking initiative to integrate advanced technology to more effectively, securely, and personally communicate his timeless wisdom, and guide people along the path of well-being and personal growth.
Interact with Dr. Chopra’s AI Twin here: Digital Deepak. Visitors can ask him questions from a subset of his published books and will even be treated to a sneak peek of his new “Digital Dharma” book, which focuses on the core role of AI in helping individuals achieve well-being and is scheduled for publication in December. Over the coming months, Dr. Chopra’s life’s work will be made available through his digital AI twin.
The partnership between Twin Protocol, Cyberhuman.ai, and Dectec is breaking new ground in the wellness industry. Cyberhuman.ai, an AI platform for personal health and well-being, optimizes lives for peak living at home, work, play, or on the road. The platform uses advanced diagnostics and predictive analytics to provide personalized well-being program recommendations. Dectec is creating the ecosystem and digital wallet that will enable users to make purchases within the ecosystem. Twin Protocol provides the decentralized digital AI twin technology for all healthcare gurus and users, the industry’s most secure, ultra-relatable means of sharing knowledge.
Dr. Chopra’s AI Twin, born out of extensive research and development by Twin Protocol, embodies his vision for guiding individuals on a journey pursuing optimal health and vitality. His AI Twin is poised to revolutionize the future of well-being by offering a holistic approach to wellness that integrates the latest security advancements in AI and blockchain technology. Future updates to the AI Twin will add new communication capabilities and modalities.
Dr. Deepak Chopra shared his perspective on the transformative potential of the AI Twin, stating, “With digital twins and AI technology, it is becoming possible to guide more and more people around the globe on a journey of ever-improving well-being and mindfulness. Over the coming weeks and months, I will share deeper insight through my twin, safely and securely empowering individuals to leverage my assistant as a confidant, health coach, and spiritual guide.”
“The launch of Dr. Deepak Chopra’s AI Twin demonstrates the exceptional vision and capabilities of the Cyberhuman.ai, Dectec, and Twin Protocol team. This is a significant milestone in our journey towards empowering individuals to live their best, most healthy lives,” said Stacey Engle, CEO of Twin Protocol. “By combining cutting-edge technology with his profound wisdom, we are pioneering a new paradigm of well-being that is accessible, personalized, and transformative.”
A unique panel will take place this week at Cannes, exploring the transformative potential of AI and digital twins in enhancing individual well-being.
June 20, 2024
11:00 AM to 12:00 PM
Annex Beach Cannes
Boulevard de la Croisette, Cannes - France
Participants:
- Deepak Chopra – MD
- Poonacha Machaiah – Co-founder, Cyberhuman.ai
- Stacey Engle – CEO, Twin Protocol
- Bill Inman – CEO, Dectec
“AI is reinventing aspects of our world in fundamental ways, including enabling us to create a future where people around the globe can instantly harness the well-being knowledge and insights of global thought leaders such as Dr. Chopra,” said Poonacha Machaiah, co-founder of Cyberhuman.ai. “Through partnerships with world-leading tech innovators like Twin Protocol and Dectec, we are democratizing well-being and helping people live their best lives.”
“When it comes to wellness and health-related information and transactions, its essential that our data is absolutely secure,” said Bill Inman, CEO, Dectec. “With our Web3 platform and collaboration with world-class partners, we’re creating a secure ecosystem that protects users and empowers them to securely manage and improve all aspects of their well-being.”
For more information about Twin Protocol, please visit Twin Protocol.
About Cyberhuman.ai
Cyberhuman.ai is a pioneering advance in personal health and well-being. It is designed as an AI platform to help individuals optimize their lives for peak living across various environments—at home, work, play, or on the road. Leveraging a combination of advanced diagnostics and predictive analytics, the platform offers personalized well-being program recommendations.
About Dectec
Dectec is a pioneering Web3 platform that connects traditional enterprises with advanced AI and blockchain technologies. Specializing in loyalty and rewards programs, Dectec empowers businesses to expand their reach and deepen customer engagement through innovative solutions like user-friendly mobile apps, metaverse experiences, and robotics. The company’s strategy focuses on tapping into new markets with a sophisticated, user-centric wallet system, ensuring clients stay at the forefront of industry innovation for sustained success.
About Twin Protocol
The mission of Twin Protocol’s global venture is to empower individuals and organizations to create secure, dynamic digital versions of themselves to share knowledge, create legacies, and foster continuous learning. Through an advanced AI and blockchain ecosystem, Twin Protocol is revolutionizing the way knowledge and expertise are preserved, shared, and utilized. Twin Protocol, along with strategic partners including SingularityNET, is committed to helping users shape a future where knowledge is an enduring and shared asset. Learn more at Twin Protocol.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620183427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom